Increasing awareness about breast density and the associated breast cancer risk is significantly changing the breast cancer screening landscape. A recent survey conducted by the 'Are You Dense' advocacy group revealed that 93% of participants would choose to have additional screening if they were informed of the presence of dense breast tissue, even if this additional screening produced false alarms [1].
NoTouch BreastScan is an FDA cleared (Feb. '12) medical innovation. The indication for use is: "adjunctive screening test for the detection of breast cancer by measuring various temperature parameters from the surface of the breast" [2].
In a recent clinical study, NoTouch BreastScan successfully detected early stage breast cancers with 87% sensitivity [3]. In 2010, a clinical study revealed that the combined sensitivity of NoTouch BreastScan and mammography in women under 50 is an encouraging 89% [4]. Click here to review the latest clinical data.
NoTouch BreastScan is the latest innovation in the field of digital infrared breast imaging. As a fully automated system, it offers touch-less and radiation-free breast evaluation for women of all ages. Incorporating a novel dual-infrared sensor feature and automated software analytics, NoTouch BreastScan is easy to operate and enables accurate reporting without the need for extensive training or radiology expertise.
See how NoTouch BreastScan is used in a doctor's office/clinic.
Return to Top
1. AuntMinnie.com August 13, 2012 "AHRA: Breast density tracking here to stay". Are You Dense Advocacy Group.
2. United States Food and Drug Administration. FDA 510(k)# K113259
3. May 2012, "Does infrared thermography predict the presence of malignancy in patients with suspicious radiologic breast abnormalities?" Download study results here.
4. EJSO 36 (2010) 535-540, European Journal of Surgical Oncology, "The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy".
